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To understand the molecular basis of the mode of action of 
organic small molecules, it is essential to identify their cellular 
target proteins. Mammalian small molecule-protein interaction 
trap (MASPIT
[1]
) provides a new tool for target-elucidation of 
small molecules, based on the cytokine-receptor-associated 
JAK-STAT-signal transduction system. 
 
 
 
We set out to synthesize alkyne-functionalized analogues of 
blockbuster drugs (simvastatin, propranolol and tamoxifen) 
and the small molecule reversine, paying close attention to 
SAR. These analogues were conjugated with an azide 
containing MTX-reagent via the Cu(I)-catalyzed Huisgen 1,3-
dipolar cycloaddition (CLICK chemistry). The resulting MTX-
conjugates are currently being evaluated in the MASPIT 
assay. 
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